Business Description
KalVista Pharmaceuticals Inc
NAICS : 325411
SIC : 2834
ISIN : US4834971032
Description
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 27.88 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -5.9 | |||||
| 3-Year EPS without NRI Growth Rate | -12.2 | |||||
| 3-Year FCF Growth Rate | -15.5 | |||||
| 3-Year Book Growth Rate | -22.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 64.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.2 | |||||
| 9-Day RSI | 39.24 | |||||
| 14-Day RSI | 42.41 | |||||
| 6-1 Month Momentum % | -3.73 | |||||
| 12-1 Month Momentum % | 44.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.55 | |||||
| Quick Ratio | 8.55 | |||||
| Cash Ratio | 7.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.3 | |||||
| Shareholder Yield % | 0.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -98.21 | |||||
| ROA % | -83.53 | |||||
| ROIC % | -694.01 | |||||
| 3-Year ROIIC % | -322043.48 | |||||
| ROC (Joel Greenblatt) % | -1573.15 | |||||
| ROCE % | -97.76 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.72 | |||||
| Price-to-Tangible-Book | 2.72 | |||||
| EV-to-EBIT | -2.45 | |||||
| EV-to-EBITDA | -2.46 | |||||
| EV-to-Forward-Revenue | 17.6 | |||||
| EV-to-FCF | -3.66 | |||||
| Price-to-Net-Current-Asset-Value | 2.8 | |||||
| Price-to-Net-Cash | 3.13 | |||||
| Earnings Yield (Greenblatt) % | -40.82 | |||||
| FCF Yield % | -19.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KALV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
KalVista Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.58 | ||
| Beta | -0.21 | ||
| Volatility % | 66.49 | ||
| 14-Day RSI | 42.41 | ||
| 14-Day ATR ($) | 0.711406 | ||
| 20-Day SMA ($) | 11.5975 | ||
| 12-1 Month Momentum % | 44.11 | ||
| 52-Week Range ($) | 7.39 - 16.88 | ||
| Shares Outstanding (Mil) | 49.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
KalVista Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
KalVista Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
KalVista Pharmaceuticals Inc Frequently Asked Questions
What is KalVista Pharmaceuticals Inc(KALV)'s stock price today?
The current price of KALV is $10.89. The 52 week high of KALV is $16.88 and 52 week low is $7.39.
When is next earnings date of KalVista Pharmaceuticals Inc(KALV)?
The next earnings date of KalVista Pharmaceuticals Inc(KALV) is 2024-12-06 Est..
Does KalVista Pharmaceuticals Inc(KALV) pay dividends? If so, how much?
KalVista Pharmaceuticals Inc(KALV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers